Page 23 - Practice Guidelines News Today

26.05.2023 - Positive high-level results from the DUO-E Phase III trial showed IMFINZI (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a ...

Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating

The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.

NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent... | May 24, 2023

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.

The National Comprehensive Cancer Network updated its recommendations to include Krazati for patients with KRAS G12-mutant pancreatic cancer.

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.

Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.

ROUYN-NORANDA, Quebec, May 18, 2023 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) is pleased to...

/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the appointment of Katy Winckworth-Prejsnar, MPH, NCCNs Senior Manager of...